



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Immediate-Release Opioid Analgesic Duration of Therapy and Quantity Limits Page: 1 of 4

Effective Date: 5/28/2025 Last Review Date: 5/2025

Applies to: ☐ Illinois ☐ Florida ☒ Florida Kids
☐ New Jersey ☐ Maryland ☐ Michigan
☒ Pennsylvania Kids ☐ Virginia ☐ Kentucky PRMD

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for immediate-release opioid analgesics for members 19 years of age and younger under the patient's prescription drug benefit.

Description:

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines for immediate-release opioid analgesics for members 19 years of age and younger. All immediate-release opioid analgesics are limited to a maximum 3-day supply and other quantity limits. The American Pain Society Opioid Treatment Guidelines state that a reasonable definition for high dose opioid therapy is greater than 200 mg daily of oral morphine (or equivalent). Requests to exceed these limits and those for any non-preferred product are subject to the criteria in this policy. Medications requested for more than 200 Morphine Milligram Equivalents (MME) per day will require a Medical Director Review.

Applicable Drug List:

Immediate-Release Opioid Analgesics

Codeine sulfate tablets
Hydromorphone hydrochloride oral solution, suppositories, tablets
Levorphanol tartrate tablets
Meperidine hydrochloride oral solution, tablets
Morphine sulfate oral solution, oral solution concentrate, suppositories, tablets
Oxycodone hydrochloride capsules, oral solution, oral solution concentrate, tablets
Oxymorphone hydrochloride tablets
Pentazocine/naloxone tablets
Tapentadol tablets
Tramadol hydrochloride oral solution, tablets

Acetaminophen/Aspirin/Ibuprofen Containing Opioid Analgesics

Acetaminophen and benzhydrocodone
Acetaminophen and codeine
Acetaminophen and hydrocodone
Acetaminophen and oxycodone
Acetaminophen and tramadol
Acetaminophen, caffeine, and dihydrocodeine
Aspirin and oxycodone
Celecoxib and tramadol



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Immediate-Release Opioid Analgesic Duration of Therapy and Quantity Limits Page: 2 of 4

Effective Date: 5/28/2025 Last Review Date: 5/2025

Applies to: ☐ Illinois ☐ Florida ☒ Florida Kids
☐ New Jersey ☐ Maryland ☐ Michigan
☒ Pennsylvania Kids ☐ Virginia ☐ Kentucky PRMD

Ibuprofen and hydrocodone

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through hospice or palliative care

AND

- If the request is for a non-preferred product, the patient is unable to take the 3 formulary alternatives for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication. Documentation is required for approval.

OR

- The patient can safely take the requested dose based on their history of opioid use. [Note: The lowest effective dosage should be prescribed for opioid naïve patients.]

AND

- The patient is 19 years of age and younger and has been evaluated and will be monitored regularly for the development of opioid use disorder

AND

- The requested drug is being prescribed for CHRONIC pain severe enough to require an opioid analgesic. [NOTE: Chronic pain is generally defined as pain that typically lasts greater than 3 months.]

AND


- The patient's pain will be reassessed in the first month after the initial prescription or any dose increase AND every 3 months thereafter to ensure that clinically meaningful improvement in pain and function outweigh risks to patient safety

OR

- The patient requires extended treatment beyond 3 days for ACUTE pain severe enough to require an opioid analgesic [NOTE: Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic.]

AND

- If the request is for a non-preferred product, the patient is unable to take the 3 formulary alternatives for the given diagnosis due to a trial and inadequate treatment

	
AETNA BETTER HEALTH® Coverage Policy/Guideline	
Name: Immediate-Release Opioid Analgesic Duration of Therapy and Quantity Limits	Page: 3 of 4
Effective Date: 5/28/2025	Last Review Date: 5/2025
Applies to: <div style="display: flex; justify-content: space-between; padding: 0 10px;"> <div> <input type="checkbox"/> Illinois <input type="checkbox"/> New Jersey <input checked="" type="checkbox"/> Pennsylvania Kids </div> <div> <input type="checkbox"/> Florida <input type="checkbox"/> Maryland <input type="checkbox"/> Virginia </div> <div> <input checked="" type="checkbox"/> Florida Kids <input type="checkbox"/> Michigan <input type="checkbox"/> Kentucky PRMD </div> </div>	

response or intolerance, or a contraindication. Documentation is required for approval.

Quantity Limits may apply.

Approval Duration and Quantity Restrictions:

Pain associated with cancer, sickle cell disease, a terminal condition, or pain being managed through hospice or palliative care: Approve 12 months

Chronic Pain: Approve 6 months

Acute Pain: 1 month

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

- Codeine Sulfate Tablets [package insert]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc.; December 2023.
- Dilaudid oral solution, tablets [package insert]. Stamford, CT: Purdue Pharma L.P.; December 2023.
- Hydromorphone HCl suppositories [package insert]. Minneapolis, MN: Padagis; September 2023.
- Levorphanol Tartrate [package insert]. Philadelphia, PA: Lannett Company, Inc.; June 2024.
- Levorphanol Tartrate [package insert]. Solana Beach, CA: Sentynl Therapeutics, Inc.; January 2021.
- Meperidine Hydrochloride oral solution, tablets [package insert]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc.; May 2024.
- Morphine Sulfate 10 mg/5 mL, 20 mg/5 mL, 100 mg/5 mL (20 mg/mL) oral solution [package insert]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc.; December 2023.
- Morphine Sulfate suppositories [package insert]. Minneapolis, MN: Padagis; July 2023.
- Morphine Sulfate tablets [package insert]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc.; December 2023.
- Nucynta tablets [package insert]. Stoughton, MA: Collegium Pharmaceutical, Inc.; December 2023.
- Oxaydo [package insert]. Lake Forest, IL: Zyla Life Sciences US LLC.; April 2024.
- Oxycodone Hydrochloride tablets [package insert]. Brookhaven, NY: Amneal Pharmaceuticals of NY, LLC; May 2024.
- Oxycodone Hydrochloride capsules [package insert]. Baudette, MN: ANI Pharmaceuticals Inc.; May 2024.
- Oxycodone Hydrochloride 5 mg/5 mL, 100 mg/5 mL (20 mg/mL) oral solution [package insert]. Webster Groves, MO: SpecGx LLC; April 2024.
- Oxymorphone [package insert]. Laurelton, NY: Epic Pharma, LLC; December 2023.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name:	Immediate-Release Opioid Analgesic Duration of Therapy and Quantity Limits	Page:	4 of 4
-------	---	-------	--------

Effective Date:	5/28/2025	Last Review Date:	5/2025
-----------------	-----------	-------------------	--------

Applies to:	<input type="checkbox"/> Illinois	<input type="checkbox"/> Florida	<input checked="" type="checkbox"/> Florida Kids
	<input type="checkbox"/> New Jersey	<input type="checkbox"/> Maryland	<input type="checkbox"/> Michigan
	<input checked="" type="checkbox"/> Pennsylvania Kids	<input type="checkbox"/> Virginia	<input type="checkbox"/> Kentucky PRMD

16. Pentazocine and Naloxone [package insert]. Somerset, NJ: Novel Laboratories, Inc; January 2024.
17. Qdolo [package insert]. Athens, GA: Athena Bioscience, LLC; December 2023.
18. RoxyBond [package insert]. Princeton, NJ: Protega Pharmaceuticals Inc., LLC; May 2024.
19. Tramadol [package insert]. East Windsor, NJ: Advagen Pharma Ltd.; August 2024.
20. Tramadol Oral Solution [package insert]. Greenville, SC: Palmetto Pharmaceuticals, Inc.; December 2023.
21. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed November 20, 2024.
22. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed November 20, 2024.
23. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 11/20/2024).
24. Palliative Care. NCCN Guidelines version 1.2025. Available at: https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf. Accessed November 21, 2024.
25. Adult Cancer Pain. NCCN Guidelines version 3.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed December 9, 2024.
26. Chou R, Fanciullo G, Fine P, et al. Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. The Journal of Pain. 2009;10:113-130.
27. Dowell D, Ragan, KR, Jones, CM, et al; CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR Recomm Rep. 2022;71:1–95. Available at: <http://dx.doi.org/10.15585/mmwr.rr7103a1>. Accessed November 21, 2024.
28. Clinical Pharmacology [database online]. Tampa, FL: Elsevier/Gold Standard; <https://www.clinicalkey.com/pharmacology/> [available with subscription]. Accessed November 21, 2024.
29. National Heart, Lung, and Blood Institute. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Available at: https://www.nhlbi.nih.gov/sites/default/files/media/docs/sickle-cell-disease-report%20020816_0.pdf. Accessed November 21, 2024.
30. Gaither, JR, Shabanova V, Leventhal JM. US National Trends in Pediatric Deaths From Prescription and Illicit Opioids, 1999-2016. JAMA Network Open. 2018;1(8):e186558.doi:10.1001/jamanetworkopen.2018.6558.
31. Meich R, Johnston L, O'Malley PM, et al. Prescription Opioids in Adolescence and Future Opioid Misuse. Pediatrics. 2015 Nov;136(5):e1169–77. doi: 10.1542/peds.2015-1364.
32. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016. MMWR Recomm Rep. 2016;65:1–49. Available at: <http://dx.doi.org/10.15585/mmwr.rr6501e1>. Accessed November 21, 2024.
33. U.S. Food & Drug Administration. FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use. April 13, 2023. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-prescribing-information-all-opioid-pain-medicines-provide-additional-guidance-safe-use>. Accessed November 21, 2024.